Xcout IntelGemmabio competitors & alternatives
The 12 closest competitors and alternatives to Gemmabio among healthcare companies — ranked by similarity to what Gemmabio actually does, not by market-cap band.
Subscribe to see Gemmabio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Gemmabio
GEMMABio is a privately held therapeutics company founded in 2024 in Philadelphia, Pennsylvania, dedicated to developing novel gene therapies for rare diseases.
Gemmabio at a glance
Gemmabio is a healthcare company headquartered in United States. Its most recent funding round, Seed, raised $34M in December 2024. Xcout tracks 6 named people at Gemmabio, including Annalisa Jenkins (Chair).
Gemmabio leadership
- Annalisa JenkinsChair
- Dr. Jim Wilsonfounder
- James M. WilsonFounder
- Campbell MurrayBoard Member
- Florent GrosBoard Member
- John MaraganoreBoard Member
Gemmabio funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $34M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Gemmabio competitors
Ranked by semantic similarity — how close each company is to Gemmabio by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar healthcare company
GEn1E Lifesciences Inc. is a clinical-stage, Phase 2 biotechnology research company based in Palo Alto, California, focused on accelerating novel precision therapies.
Similar healthcare company
Spot Biosystems is a gene therapy company pioneering a novel non-viral extracellular delivery approach. Headquartered in Palo Alto, California, the company launched with significant financing to advance its therapeutic pipeline.
Similar healthcare company
GENEOS Therapeutics, Inc. is a biotechnology company focused on developing exquisitely personalized, EPIC-based cancer immunotherapies. The company is headquartered in Philadelphia, Pennsylvania, United States.
Similar healthcare company
Belief BioMed Inc. is a globally innovative biotechnology company that integrates the development, manufacturing, and clinical application of gene therapy products. The company operates research centers, manufacturing facilities, and offices across multiple cities in China as well as the United States. Its primary operations are rooted in Shanghai, China.
Similar healthcare company
GenEdit is a South San Francisco, California-based startup developing alternative methods of delivering gene-based and CRISPR-based medicines.
Biotechnology
Code Biotherapeutics, Inc. is a biotechnology company headquartered in the Greater Philadelphia area. The firm focuses on next-generation gene therapies and advanced medicine.
Biotechnology
Homology Medicines, Inc. is a clinical-stage genetic medicines company historically focused on transforming the lives of patients with rare diseases through genetic treatments.
Biotechnology
Kriya Therapeutics, Inc. is a fully integrated biopharmaceutical company with operational footprints in Redwood City, California, and Research Triangle Park, North Carolina. The company develops novel gene therapies to address diverse diseases.
Biotech
SpliceBio is a clinical-stage genetic medicines company that develops gene therapies using a proprietary Protein Splicing platform. The company focuses on treating diseases caused by mutations in large genes, with a lead clinical program targeting Stargardt disease.
Biotechnology
Carmine Therapeutics, Inc. is an EVX Ventures company headquartered in Cambridge, Massachusetts, focused on developing novel gene therapies.
Biotechnology
Averna Therapeutics is a biotechnology company developing genomic medicines utilizing RNA and lipid nanoparticle technologies. The company focuses on safe and efficient gene insertion and the treatment of rare genetic diseases through research and development teams located in Boston and Israel.
Biotech
AAVantgarde Bio is an Italian biotechnology company developing adeno-associated virus (AAV) gene therapies for rare genetic diseases, including conditions caused by genes too large to fit into a single AAV vector. Its technology uses dual-AAV approaches to deliver larger therapeutic genes, serving patients with serious inherited disorders and the clinicians who treat them.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Gemmabio and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Gemmabioand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →